| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Bisoprolol-d5 targets the same molecular target as its non-deuterated form, the β₁-adrenergic receptor. Bisoprolol is a cardioselective β₁-adrenoceptor antagonist that blocks the effects of catecholamines (adrenaline and noradrenaline) on the heart. It has minimal activity at β₂-receptors, which are predominantly found in the bronchi and peripheral vasculature. By blocking β₁-receptors, bisoprolol reduces heart rate, cardiac output, and blood pressure. The labeled compound is used as a tracer to study the pharmacokinetics and metabolism of bisoprolol.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
The deuterated compound itself does not possess intrinsic pharmacological activity in vitro; its biological activity is identical to that of bisoprolol. Bisoprolol is a selective β₁-adrenoceptor antagonist with high affinity for the β₁-receptor (Kᵢ ≈ 10 nM) and significantly lower affinity for β₂-receptors. In vitro studies have demonstrated that bisoprolol effectively inhibits isoproterenol-stimulated cAMP accumulation in cells expressing β₁-receptors. The labeled compound is used as an internal standard for quantifying bisoprolol in biological samples, not for evaluating its own pharmacological activity. |
| ln Vivo |
Bisoprolol-d5 is not used as a therapeutic agent; its non-deuterated form, bisoprolol, is an orally active β₁-blocker used in the treatment of hypertension, coronary artery disease, and stable ventricular dysfunction. Bisoprolol has been shown to reduce mortality in patients with heart failure. In vivo, bisoprolol is well-absorbed after oral administration and undergoes extensive hepatic metabolism. The labeled compound is used in pharmacokinetic studies to accurately measure bisoprolol concentrations in plasma and other biological matrices.
|
| Enzyme Assay |
In vitro receptor binding assays for bisoprolol-d5 are not standard, as it is an analytical standard. However, the activity of its non-deuterated form can be assessed using competition binding assays with [³H]CGP-12177 or [¹²⁵I]iodocyanopindolol as radioligands. Membranes prepared from cells expressing β₁-adrenergic receptors are incubated with varying concentrations of bisoprolol and the radioligand. Non-specific binding is determined in the presence of excess propranolol. Bound radioactivity is separated by filtration and quantified by scintillation counting. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
In vitro cell culture experiments are not performed with bisoprolol-d5. When studying the effects of bisoprolol in cellular systems, the non-labeled compound is used. Cells expressing β₁-adrenergic receptors (e.g., HEK-293 cells) are treated with bisoprolol at concentrations ranging from 1 nM to 100 µM, and cAMP levels are measured by ELISA or HTRF assays. The labeled compound is used as an internal standard for LC-MS/MS analysis of bisoprolol concentrations in cell culture media or lysates.
|
| Animal Protocol |
In vivo animal studies with bisoprolol-d5 are not conducted, as it is an analytical standard. When used in pharmacokinetic studies, the labeled compound serves as an internal standard for the quantification of bisoprolol in animal plasma or tissue samples. In typical protocols, animals (e.g., rats or dogs) are administered bisoprolol, and blood samples are collected at various time points. The labeled internal standard is added to the samples before analysis by LC-MS/MS to ensure accurate and precise quantification.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of bisoprolol-d5 itself are not characterized, as it is not a drug substance. Bisoprolol has a bioavailability of approximately 80-90% after oral administration, with a half-life of 9-12 hours in humans. It is metabolized primarily by cytochrome P450 2D6 and 3A4 to inactive metabolites. Bisoprolol is excreted in both urine and feces. The deuterated compound is used as an internal standard to accurately quantify bisoprolol in pharmacokinetic studies.
|
| Toxicity/Toxicokinetics |
Bisoprolol-d5 is not a therapeutic agent and has not been evaluated for toxicity in humans. Its non-deuterated form, bisoprolol, is generally well-tolerated, with common side effects including bradycardia, hypotension, fatigue, and dizziness. Contraindications include cardiogenic shock, severe bradycardia, and decompensated heart failure. The deuterated compound is for research use only and should be handled with standard laboratory precautions, including the use of gloves and safety glasses.
|
| References |
|
| Additional Infomation |
Bisoprolol-d5 is a stable isotope-labeled internal standard used in pharmacokinetic and metabolic studies of bisoprolol. It is also known as (±)-bisoprolol-d5. The compound is used in analytical method development, method validation, and quality control applications for generic drug products. The incorporation of deuterium allows for accurate quantification of bisoprolol in biological samples using mass spectrometry, as the labeled and unlabeled compounds have identical chemical properties but different masses.
|
| Molecular Formula |
C18H31NO4
|
|---|---|
| Molecular Weight |
325.443045854568
|
| Exact Mass |
330.256
|
| CAS # |
1189881-87-5
|
| Related CAS # |
Bisoprolol;66722-44-9
|
| PubChem CID |
46780839
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
1.9
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
23
|
| Complexity |
278
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])(C([2H])(C([2H])([2H])OC1=CC=C(C=C1)COCCOC(C)C)O)NC(C)C
|
| InChi Key |
VHYCDWMUTMEGQY-FFNOJTKMSA-N
|
| InChi Code |
InChI=1S/C18H31NO4/c1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4/h5-8,14-15,17,19-20H,9-13H2,1-4H3/i11D2,13D2,17D
|
| Chemical Name |
1,1,2,3,3-pentadeuterio-1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0728 mL | 15.3638 mL | 30.7276 mL | |
| 5 mM | 0.6146 mL | 3.0728 mL | 6.1455 mL | |
| 10 mM | 0.3073 mL | 1.5364 mL | 3.0728 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
